Detail akcie Armata Pharma Rg online

Business Summary: Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Armata Pharmaceuticals Inc revenues decreased 3% to $3.8M. Net loss increased from $21.5M to $49.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects bacteriophage therapeutics segment loss increase of 5% to $22.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.60 to -$1.37.